CTAD Boston 2-4, 2017
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge.
154 avenue de Lodève
508 776 192 00017
The general structure, the texts, the animates pictures or not, and all other element part of the site are the exclusive property of CtaD and are protected by copyright. Every copy of the site (total or partial), by any ways, without CtaD approbation, is forbiden and would constitute a counterfeit. Labels, comercials names and logos appearing on this site, are proprietaries names except contrary mention. Every copy of the logos or the labels (total or partial) done from the elements within the site, without CtaD approbation, is forbiden.
Every link to this site and every use of the CtaD's logo must be first allowed and writen before use. Despite of the CTAD's giving cares, the Informations included in this site are given as an indicative point, and are prone to changing without advance notice. As a consequence, the user admit to use those informations under his unique responsability. The user is informed that he could receive informations about favours proposed by CtaD. The entirety of the element part of the site are protected by copyright "CtaD".
31 rue de la Frébardière
Tél : 02 99 22 83 40
Mail : email@example.com